The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy
Abstract Background Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulopathy worldwide, and lacks the effective treatment. The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin converting enzyme inhibitor / angiotens...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-023-03106-4 |
| _version_ | 1797860052442284032 |
|---|---|
| author | Liping Sun Xinyi Zi Zhen Wang Xinzhou Zhang |
| author_facet | Liping Sun Xinyi Zi Zhen Wang Xinzhou Zhang |
| author_sort | Liping Sun |
| collection | DOAJ |
| description | Abstract Background Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulopathy worldwide, and lacks the effective treatment. The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (ACEI/ARB) in the treatment of IgAN. Methods 142 patients with biopsy-proven IgAN at Shenzhen People?s hospital from June 2018 to June 2020 were enrolled. The patients were randomly divided into the supportive care plus fluticasone group and the supportive care group. The patients of the supportive care plus fluticasone group were treated with fluticasone propionate aerosol (250 ?g Bid) combined with ACEI/ARB, while the supportive care group was merely treated with ACEI/ARB. The patients were followed up at 3, 6 and 9 months after enrollment. Primary outcomes include changes in proteinuria and estimated glomerular filtration rate (eGFR). Results The level of proteinuria in the supportive care plus fluticasone group was significantly lower compared with the supportive care group at 0, 3, 6 and 9 months. Meanwhile, during the follow-up period, no serious adverse events were recorded during the study in either group. However, fluticasone treatment did not alleviate the decline in eGFR. Conclusion Fluticasone propionate aerosol combined with ACEI/ARB can reduce the level of proteinuria in thetreatment of IgAN, and has no significant effects on renal function. |
| first_indexed | 2024-04-09T21:39:30Z |
| format | Article |
| id | doaj.art-ddb9dcb192d34be4bb05b2a23c140ca2 |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-04-09T21:39:30Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-ddb9dcb192d34be4bb05b2a23c140ca22023-03-26T11:07:47ZengBMCBMC Nephrology1471-23692023-03-012411510.1186/s12882-023-03106-4The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathyLiping Sun0Xinyi Zi1Zhen Wang2Xinzhou Zhang3Department of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan UniversityDepartment of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan UniversityDepartment of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan UniversityDepartment of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan UniversityAbstract Background Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulopathy worldwide, and lacks the effective treatment. The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (ACEI/ARB) in the treatment of IgAN. Methods 142 patients with biopsy-proven IgAN at Shenzhen People?s hospital from June 2018 to June 2020 were enrolled. The patients were randomly divided into the supportive care plus fluticasone group and the supportive care group. The patients of the supportive care plus fluticasone group were treated with fluticasone propionate aerosol (250 ?g Bid) combined with ACEI/ARB, while the supportive care group was merely treated with ACEI/ARB. The patients were followed up at 3, 6 and 9 months after enrollment. Primary outcomes include changes in proteinuria and estimated glomerular filtration rate (eGFR). Results The level of proteinuria in the supportive care plus fluticasone group was significantly lower compared with the supportive care group at 0, 3, 6 and 9 months. Meanwhile, during the follow-up period, no serious adverse events were recorded during the study in either group. However, fluticasone treatment did not alleviate the decline in eGFR. Conclusion Fluticasone propionate aerosol combined with ACEI/ARB can reduce the level of proteinuria in thetreatment of IgAN, and has no significant effects on renal function.https://doi.org/10.1186/s12882-023-03106-4IgA nephropathyFluticasone propionate aerosolProteinuriaClinical efficacy |
| spellingShingle | Liping Sun Xinyi Zi Zhen Wang Xinzhou Zhang The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy BMC Nephrology IgA nephropathy Fluticasone propionate aerosol Proteinuria Clinical efficacy |
| title | The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy |
| title_full | The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy |
| title_fullStr | The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy |
| title_full_unstemmed | The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy |
| title_short | The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy |
| title_sort | clinical efficacy of fluticasone propionate combined with acei arb in the treatment of immunoglobulin a nephropathy |
| topic | IgA nephropathy Fluticasone propionate aerosol Proteinuria Clinical efficacy |
| url | https://doi.org/10.1186/s12882-023-03106-4 |
| work_keys_str_mv | AT lipingsun theclinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT xinyizi theclinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT zhenwang theclinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT xinzhouzhang theclinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT lipingsun clinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT xinyizi clinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT zhenwang clinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy AT xinzhouzhang clinicalefficacyoffluticasonepropionatecombinedwithaceiarbinthetreatmentofimmunoglobulinanephropathy |